Finding the "killer app" for treating obese individuals has seen no shortage of efforts result in failure over the years. The slow start of VIVUS' (VVUS +0.00%) Qsymia has investors doubting the market potential of both it and Arena Pharmaceuticals' (ARNA +0.00%) new drugs targeting the problem. In the following video, health care bureau chief Brenton Flynn runs through yet another example of a novel obesity  treatment approach that seems destined for failure from EnteroMedics (NASDAQ: ETRM).